Crinetics Pharmaceuticals
CRNX
CRNX was delisted on the 31st of August, 2026.
118 hedge funds and large institutions have $1.26B invested in Crinetics Pharmaceuticals in 2021 Q4 according to their latest regulatory filings, with 31 funds opening new positions, 59 increasing their positions, 19 reducing their positions, and 7 closing their positions.
350% more funds holding in top 10
Funds holding in top 10: 2 → 9 (+7)
343% more first-time investments, than exits
New positions opened: 31 | Existing positions closed: 7
211% more repeat investments, than reductions
Existing positions increased: 59 | Existing positions reduced: 19
77% more capital invested
Capital invested by funds: $708M → $1.26B (+$548M)
26% more funds holding
Funds holding: 94 → 118 (+24)
5.99% more ownership
Funds ownership: 87.22% → 93.21% (+6%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BI
BVF Inc
San Francisco,
California
|
+$50.5M |
| 2 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
+$44.3M |
| 3 |
PA
Perceptive Advisors
New York
|
+$29.6M |
| 4 |
BlackRock
New York
|
+$16.3M |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
+$16.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$17.4M |
| 2 |
5VM
5AM Venture Management
San Francisco,
California
|
-$12.3M |
| 3 |
VC
Vivo Capital
Palo Alto,
California
|
-$10.9M |
| 4 |
VVM
Versant Venture Management
San Francisco,
California
|
-$10.1M |
| 5 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$3.09M |
CRNX Hedge Fund Activity: Q4 2021 in Review
118 of the 6,518 institutional investors tracked by Wall St. Rank reported a position in Crinetics Pharmaceuticals (CRNX) for Q4 2021, worth a combined $1.26B — up 77% from $708M a quarter earlier.
Buyers outnumbered sellers: 31 funds opened new CRNX positions and 7 closed out — a net gain of 24 holders — while 59 added to existing stakes and 19 trimmed.
The largest buyer was BVF Inc, adding an estimated $50.5M. The largest seller was Fidelity Investments, cutting an estimated $17.4M.
- 118 institutional investors held Crinetics Pharmaceuticals (CRNX) as of Q4 2021, up from 94 in Q3 2021.
- Funds reported $1.26B of Crinetics Pharmaceuticals stock for Q4 2021, up 77% quarter-over-quarter.
- 31 funds opened new Crinetics Pharmaceuticals positions in Q4 2021 and 7 closed out, a net change of +24 holders.
- The largest Crinetics Pharmaceuticals buyer in Q4 2021 was BVF Inc, an estimated $50.5M added.
- The largest Crinetics Pharmaceuticals seller in Q4 2021 was Fidelity Investments, an estimated $17.4M sold.
Based on aggregated 13F filings for Q4 2021.